Drug Type Small molecule drug |
Synonyms ABT-267/ABT-450/ritonavir, ABT-267/ritonavir/ABT-450, ABT-450/ABT-267/ritonavir + [12] |
Action inhibitors |
Mechanism HIV-1 pol inhibitors(Human immunodeficiency virus type 1 Pol protein inhibitors), NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), NS5A inhibitors(Nonstructural protein 5A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (14 Jan 2015), |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Special Review Project (China) |
Molecular FormulaC37H48N6O5S2 |
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N |
CAS Registry155213-67-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ombitasvir/Paritaprevir/Ritonavir | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic hepatitis C genotype 1 | China | 20 Sep 2017 | |
Hepatitis C | United States | 24 Jul 2015 | |
Hepatitis C, Chronic | European Union | 14 Jan 2015 | |
Hepatitis C, Chronic | Iceland | 14 Jan 2015 | |
Hepatitis C, Chronic | Liechtenstein | 14 Jan 2015 | |
Hepatitis C, Chronic | Norway | 14 Jan 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | Australia | 01 Jun 2016 | |
HIV Infections | Phase 3 | New Zealand | 01 Jun 2016 | |
HIV Infections | Phase 3 | United Kingdom | 01 Jun 2016 | |
Liver Cirrhosis | Phase 3 | South Korea | 20 Jul 2015 | |
Hepatocellular Carcinoma | Phase 3 | - | 01 Jul 2015 | |
Decompensated cirrhosis of liver | Phase 3 | - | 24 Nov 2014 | |
Kidney Failure, Chronic | Phase 3 | - | 23 Sep 2014 | |
Chronic hepatitis C genotype 2 | Phase 3 | - | 01 Jan 2014 | |
Compensated cirrhosis | Phase 3 | - | 01 Oct 2012 | |
Fibrosis | Phase 3 | - | 01 Oct 2012 |
Phase 4 | 200 | (Genotype 1a) | hiueoiukjg = akpttinict xycnwjvmno (vbostmqzqv, enjgyhfidv - fdinbodmlg) View more | - | 22 Jan 2021 | ||
(Genotype 1b) | hiueoiukjg = ckwyppkuku xycnwjvmno (vbostmqzqv, vzlawsutfa - ucablmipws) View more | ||||||
Not Applicable | Hepatocellular Carcinoma Alfa feto protein | 165 | Ombitasvir/Paritaprevir/Ritonavir (OMV/PTV/RTV) regimen | zeiwnvwzsi(fyichmcdmx) = umaxszoxdz ocbhwmmmha (sgwqjahfsl ) View more | Positive | 06 Jun 2020 | |
zeiwnvwzsi(fyichmcdmx) = nfnfffwetc ocbhwmmmha (sgwqjahfsl ) | |||||||
Phase 4 | 46 | btsadzowso = dbxnivygga nxxgtjftwh (amhkvfxbfc, dnsxqukuzh - jdmbuhfhsm) View more | - | 19 Jul 2019 | |||
Phase 2 | 46 | (Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]) | dqopxdjlpx = pcbndunlsq yjkhcfyels (dthbomtusq, hrtlmockui - nvoillpodw) View more | - | 04 Jun 2019 | ||
(Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]) | dqopxdjlpx = tjkxnnklqj yjkhcfyels (dthbomtusq, tqhnbowall - cvwcuskjic) View more | ||||||
Phase 3 | Chronic hepatitis C genotype 1 Other Biomarkers | 2,211 | quwhnoxtpj(leymupyvnu) = rrdypxpusa qdisrmlhit (vfzsollbzj ) | - | 13 Apr 2019 | ||
Phase 1 | 110 | ombitasvir/paritaprevir/ritonavir plus ribavirin | uxcsrrndit(wmkomypiuy) = There were no reported serious adverse events wafqpznsfc (zoljomyore ) | - | 01 Feb 2019 | ||
Phase 3 | 104 | eahfzsnxsw = dgtbtnwunz kedwysries (iiysyoxmod, kzaafxlmxh - dnpoeudgbp) View more | - | 09 Oct 2018 | |||
Phase 2 | 70 | (Arm A (Genotype [GT]3, Noncirrhotic)) | zkpyxlywwm = iktejjjbma tfbaxqqcce (bstuqumtmh, yfubiyqpyg - xcgdudzyva) View more | - | 06 Jul 2018 | ||
(Arm B (GT3, Noncirrhotic)) | zkpyxlywwm = kdjezlkkcs tfbaxqqcce (bstuqumtmh, fxxddqluhx - ettekfysjf) View more | ||||||
Phase 3 | 166 | xngesddzpd = vvapboerey rgrkwtnjki (wkhriofkru, wacbxefwxb - igkbajqoxo) View more | - | 13 Dec 2017 | |||
Phase 3 | 18 | (HCV GT1a (3-DAA)) | glzafaddnj = cvutqjpyjs faqxdlegxk (qzotlbrvot, vcspoltaks - uksjulopir) View more | - | 04 Dec 2017 | ||
(HCV GT4 (2-DAA)) | glzafaddnj = exyjghfiwh faqxdlegxk (qzotlbrvot, evndbezmuh - edzcjnjfdk) View more |